Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07768358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07768358 · ClinicalTrials.gov record · last posted 2026-08-17

Tucatinib Continuation Study

Name: Tucatinib Continuation Study — clinical trial record (NCT07768358)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorPfizer

Started2026-08-24

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.

Trial Details

NCT Number	NCT07768358
Lead Sponsor	Pfizer
Conditions	HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Enrollment	175 participants
Start Date	2026-08-24
Primary Completion	2032-03-13 (estimated)
Study Completion	2032-03-13 (estimated)
Updated on ClinicalTrials.gov	2026-08-17